Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing

  • Sang Mee Hwang (Department of Laboratory Medicine, Seoul National University Bundang Hospital) ;
  • Inseong Oh (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Seok Ryun Kwon (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Jee-Soo Lee (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Moon-Woo Seong (Department of Laboratory Medicine, Seoul National University College of Medicine)
  • Received : 2023.10.17
  • Accepted : 2024.01.06
  • Published : 2024.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Measurable residual disease (MRD) testing, a standard procedure in B-lymphoblastic leukemia (B-ALL) diagnostics, is assessed using multiparametric flow cytometry (MFC) and next-generation sequencing (NGS) analysis of immunoglobulin gene rearrangements. We evaluated the concordance between eight-color, two-tube MFC-MRD the LymphoTrack NGS-MRD assays using 139 follow-up samples from 54 pediatric patients with B-ALL. We also assessed the effect of hemodilution in MFC-MRD assays. The MRD-concordance rate was 79.9% (N=111), with 25 (18.0%) and 3 (2.2%) samples testing positive only by NGS-MRD (MFC-NGS+MRD) and MFC-MRD (MFC+NGS-MRD), respectively. We found a significant correlation in MRD values from total nucleated cells between the two methods (r=0.736 [0.647-0.806], P <0.001). The median MRD value of MFC-NGS+MRD samples was estimated to be 0.0012% (0.0001%-0.0263%) using the NGS-MRD assays. Notably, 14.3% of MFC-NGS+MRD samples showed NGS-MRD values below the limit of detection in the MFC-MRD assays. The percentages of hematogones detected in MFC-MRD assays significantly differed between the discordant and concordant cases (P <0.001). MFC and NGS-MRD assays showed relatively high concordance and correlation in MRD assessment, whereas the NGS-MRD assay detected MRD more frequently than the MFC-MRD assay in pediatric B-ALL. Evaluating the hematogone percentages can aid in assessing the impact of sample hemodilution.

Keywords

Acknowledgement

This study was supported by the SNUBH research fund (grant number 02-2021-0051).

References

  1. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18:81-112. https://doi.org/10.6004/jnccn.2020.0001
  2. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol 2017;3:e170580. https://doi.org/10.1001/jamaoncol.2017.0580
  3. Cherian S and Soma LA. How I diagnose minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma by flow cytometry. Am J Clin Pathol 2021;155:38-54. https://doi.org/10.1093/ajcp/aqaa242
  4. Kim HY, Yoo IY, Lim DJ, Kim HJ, Kim SH, Yoon SE, et al. Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Ann Lab Med. 2022;42:558-65. https://doi.org/10.3343/alm.2022.42.5.558
  5. Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 2017;129:347-57. https://doi.org/10.1182/blood-2016-07-726307
  6. Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 2018;131:1350-9. https://doi.org/10.1182/blood-2017-09-806521
  7. Paulsen K, Marincevic M, Cavelier L, Hollander P, Amini RM. LymphoTrack is equally sensitive as PCR GeneScan and Sanger sequencing for detection of clonal rearrangements in ALL patients. Diagnostics (Basel) 2022;12:1389. https://doi.org/10.3390/diagnostics12061389
  8. Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 2014;20:4540-8. https://doi.org/10.1158/1078-0432.CCR-13-3231
  9. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 2022;6:4006-14. https://doi.org/10.1182/bloodadvances.2022007378
  10. Cheng S, Inghirami G, Cheng S, and Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol 2018;11:105. https://doi.org/10.1186/s13045-018-0652-y
  11. Cherian S, Miller V, McCullouch V, Dougherty K, Fromm JR, Wood BL. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom 2018;94:112-20. https://doi.org/10.1002/cyto.b.21482
  12. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31:2094-103. https://doi.org/10.1038/leu.2017.29
  13. Momen N, Tario J, Fu K, Qian YW. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease. J Hematopathol 2023;16:85-94. https://doi.org/10.1007/s12308-023-00544-9
  14. Chen W, Karandikar NJ, McKenna RW, Kroft SH. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. Am J Clin Pathol 2007;127:39-46. https://doi.org/10.1309/7R6MU7R9YWJBY5V4
  15. Lee JW, Kim Y, Ahn A, Lee JM, Yoo JW, Kim S, et al. Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia. Front Oncol 2022;12:957743. https://doi.org/10.3389/fonc.2022.957743
  16. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom 2008;74:331-40. https://doi.org/10.1002/cyto.b.20430
  17. Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, et al. Comparison of NGS and MFC methods: Key metrics in multiple myeloma MRD assessment. Cancers (Basel). 2020;12:2322. https://doi.org/10.3390/cancers12082322
  18. Hoffmann J, Thrun MC, Röhnert MA, von Bonin M, Oelschlägel U, Neubauer A, et al. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: the Cinderella method. Cytometry A 2023;103:304-12. https://doi.org/10.1002/cyto.a.24686
  19. Mai H, Li Q, Wang G, Wang Y, Liu S, Tang X, et al. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2023;149:3259-66. https://doi.org/10.1007/s00432-022-04151-6